Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock

Kanika P. Mody, Hiroo Takayama, Elissa Landes, Melana Yuzefpolskaya, Paolo C. Colombo, Yoshifumi Naka, Ulrich P. Jorde, Nir Uriel

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In fulminant myocarditis complicated by cardiogenic shock, early mechanical circulatory support (MCS) may prevent cardiomyopathy and death. We sought to examine the outcomes of patients with fulminant myocarditis supported with MCS. A retrospective review of patients with acute cardiogenic shock treated with MCS from 2007 to 2013 was conducted, and patients with a diagnosis of fulminant myocarditis were included in this series. At our center, 260 patients received MCS for acute cardiogenic shock, and 11 were implanted for fulminant myocarditis. Eight received the Centrimag biventricular assist device (BIVAD), and three received veno-arterial extracorporeal membrane oxygenator (VA ECMO), though 1 VA ECMO-supported patient was transitioned to BIVAD due to refractory shock. The mean acute support time was 14.7±4.4 days. Two patients required long-term left ventricular assist devices and were further supported for 55 and 112 days. Eight patients recovered with a mean ejection fraction of 54±7 %, and one was successfully transplanted. Eight patients survived to discharge (73 %) with mean follow-up: 292.6±306.8 days. All three deaths were due to neurologic complications. MCS should be considered in patients with fulminant myocarditis complicated by shock. With aggressive medical therapy, early utilization of MCS carries promising outcomes.

Original languageEnglish (US)
Pages (from-to)156-164
Number of pages9
JournalJournal of Cardiovascular Translational Research
Volume7
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Cardiogenic Shock
Myocarditis
Membrane Oxygenators
Shock
Equipment and Supplies
Heart-Assist Devices
Cardiomyopathies
Nervous System

Keywords

  • Acute mechanical circulatory support
  • Cardiogenic shock
  • Fulminant myocarditis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Mody, K. P., Takayama, H., Landes, E., Yuzefpolskaya, M., Colombo, P. C., Naka, Y., ... Uriel, N. (2014). Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock. Journal of Cardiovascular Translational Research, 7(2), 156-164. https://doi.org/10.1007/s12265-013-9521-9

Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock. / Mody, Kanika P.; Takayama, Hiroo; Landes, Elissa; Yuzefpolskaya, Melana; Colombo, Paolo C.; Naka, Yoshifumi; Jorde, Ulrich P.; Uriel, Nir.

In: Journal of Cardiovascular Translational Research, Vol. 7, No. 2, 2014, p. 156-164.

Research output: Contribution to journalArticle

Mody, Kanika P. ; Takayama, Hiroo ; Landes, Elissa ; Yuzefpolskaya, Melana ; Colombo, Paolo C. ; Naka, Yoshifumi ; Jorde, Ulrich P. ; Uriel, Nir. / Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock. In: Journal of Cardiovascular Translational Research. 2014 ; Vol. 7, No. 2. pp. 156-164.
@article{05f61e08608f46f8b406c509a5c74c93,
title = "Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock",
abstract = "In fulminant myocarditis complicated by cardiogenic shock, early mechanical circulatory support (MCS) may prevent cardiomyopathy and death. We sought to examine the outcomes of patients with fulminant myocarditis supported with MCS. A retrospective review of patients with acute cardiogenic shock treated with MCS from 2007 to 2013 was conducted, and patients with a diagnosis of fulminant myocarditis were included in this series. At our center, 260 patients received MCS for acute cardiogenic shock, and 11 were implanted for fulminant myocarditis. Eight received the Centrimag biventricular assist device (BIVAD), and three received veno-arterial extracorporeal membrane oxygenator (VA ECMO), though 1 VA ECMO-supported patient was transitioned to BIVAD due to refractory shock. The mean acute support time was 14.7±4.4 days. Two patients required long-term left ventricular assist devices and were further supported for 55 and 112 days. Eight patients recovered with a mean ejection fraction of 54±7 {\%}, and one was successfully transplanted. Eight patients survived to discharge (73 {\%}) with mean follow-up: 292.6±306.8 days. All three deaths were due to neurologic complications. MCS should be considered in patients with fulminant myocarditis complicated by shock. With aggressive medical therapy, early utilization of MCS carries promising outcomes.",
keywords = "Acute mechanical circulatory support, Cardiogenic shock, Fulminant myocarditis",
author = "Mody, {Kanika P.} and Hiroo Takayama and Elissa Landes and Melana Yuzefpolskaya and Colombo, {Paolo C.} and Yoshifumi Naka and Jorde, {Ulrich P.} and Nir Uriel",
year = "2014",
doi = "10.1007/s12265-013-9521-9",
language = "English (US)",
volume = "7",
pages = "156--164",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Acute mechanical circulatory support for fulminant myocarditis complicated by cardiogenic shock

AU - Mody, Kanika P.

AU - Takayama, Hiroo

AU - Landes, Elissa

AU - Yuzefpolskaya, Melana

AU - Colombo, Paolo C.

AU - Naka, Yoshifumi

AU - Jorde, Ulrich P.

AU - Uriel, Nir

PY - 2014

Y1 - 2014

N2 - In fulminant myocarditis complicated by cardiogenic shock, early mechanical circulatory support (MCS) may prevent cardiomyopathy and death. We sought to examine the outcomes of patients with fulminant myocarditis supported with MCS. A retrospective review of patients with acute cardiogenic shock treated with MCS from 2007 to 2013 was conducted, and patients with a diagnosis of fulminant myocarditis were included in this series. At our center, 260 patients received MCS for acute cardiogenic shock, and 11 were implanted for fulminant myocarditis. Eight received the Centrimag biventricular assist device (BIVAD), and three received veno-arterial extracorporeal membrane oxygenator (VA ECMO), though 1 VA ECMO-supported patient was transitioned to BIVAD due to refractory shock. The mean acute support time was 14.7±4.4 days. Two patients required long-term left ventricular assist devices and were further supported for 55 and 112 days. Eight patients recovered with a mean ejection fraction of 54±7 %, and one was successfully transplanted. Eight patients survived to discharge (73 %) with mean follow-up: 292.6±306.8 days. All three deaths were due to neurologic complications. MCS should be considered in patients with fulminant myocarditis complicated by shock. With aggressive medical therapy, early utilization of MCS carries promising outcomes.

AB - In fulminant myocarditis complicated by cardiogenic shock, early mechanical circulatory support (MCS) may prevent cardiomyopathy and death. We sought to examine the outcomes of patients with fulminant myocarditis supported with MCS. A retrospective review of patients with acute cardiogenic shock treated with MCS from 2007 to 2013 was conducted, and patients with a diagnosis of fulminant myocarditis were included in this series. At our center, 260 patients received MCS for acute cardiogenic shock, and 11 were implanted for fulminant myocarditis. Eight received the Centrimag biventricular assist device (BIVAD), and three received veno-arterial extracorporeal membrane oxygenator (VA ECMO), though 1 VA ECMO-supported patient was transitioned to BIVAD due to refractory shock. The mean acute support time was 14.7±4.4 days. Two patients required long-term left ventricular assist devices and were further supported for 55 and 112 days. Eight patients recovered with a mean ejection fraction of 54±7 %, and one was successfully transplanted. Eight patients survived to discharge (73 %) with mean follow-up: 292.6±306.8 days. All three deaths were due to neurologic complications. MCS should be considered in patients with fulminant myocarditis complicated by shock. With aggressive medical therapy, early utilization of MCS carries promising outcomes.

KW - Acute mechanical circulatory support

KW - Cardiogenic shock

KW - Fulminant myocarditis

UR - http://www.scopus.com/inward/record.url?scp=84896396341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896396341&partnerID=8YFLogxK

U2 - 10.1007/s12265-013-9521-9

DO - 10.1007/s12265-013-9521-9

M3 - Article

VL - 7

SP - 156

EP - 164

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 2

ER -